The generic drug Posaconazole delayed-release tablets (100mg) Regulatory Approval in Singapore

    Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been granted approval from the Health Sciences Authority (HSA) in Singapore.

    Up to now, the product has been marketed in China, the United States and Australia. The approval of the product in Singapore will bring a positive impact on company’s business growth overseas.



About SinoT

    SinoT is a specialty pharma with focus on the research & development, commercialization and sale of complex generics and 505(b2) products. We dedicated to developing high quality medicines that meet with international standards. We’ll do more than our best to benefit the patients in the future.


    About PosaconazolePOSACONAZOLE is a member of the group of triazole antifungals,which is used to prevent certain kinds of fungal or yeast infections. With the increasing number of high-risk patients such as cancer chemotherapy, transplantation, HIV/AIDS infection, and diabetes, the overall incidence of invasive fungal infections (IFIs) continues to rise. Different from other drugs used to treat IFIs, posaconazole can be used to prevent IFIs , so it has a broad market prospect.

Shanghai Head Office

Greenland Being Fun Plaza, Bldg. 1, Rm. 207, Pudong New District, Shanghai

Manufacturing Site inJiangsu

No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province

Copyright © 2014-2022 SINOTHERAPEUTICS.COM ICP:13048014-1   Powered by Yongsy

Privacy Legal